HRP20070094T3 - NOVI 14- i 15-EROČLANI PRSTENASTI SPOJEVI - Google Patents

NOVI 14- i 15-EROČLANI PRSTENASTI SPOJEVI

Info

Publication number
HRP20070094T3
HRP20070094T3 HR20070094T HRP20070094T HRP20070094T3 HR P20070094 T3 HRP20070094 T3 HR P20070094T3 HR 20070094 T HR20070094 T HR 20070094T HR P20070094 T HRP20070094 T HR P20070094T HR P20070094 T3 HRP20070094 T3 HR P20070094T3
Authority
HR
Croatia
Prior art keywords
optionally substituted
hydrogen
6alkyl
groups
hydroxy
Prior art date
Application number
HR20070094T
Other languages
English (en)
Croatian (hr)
Inventor
Alihodzic Sulejman
Michael Berge John
Lewis Jarvest Richard
Original Assignee
Glaxo Group Limited
Glaxosmithkline Istrazivacki Centar Zagreb D.O.O.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0310962A external-priority patent/GB0310962D0/en
Priority claimed from GB0407391A external-priority patent/GB0407391D0/en
Application filed by Glaxo Group Limited, Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. filed Critical Glaxo Group Limited
Publication of HRP20070094T3 publication Critical patent/HRP20070094T3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
HR20070094T 2003-05-13 2004-05-11 NOVI 14- i 15-EROČLANI PRSTENASTI SPOJEVI HRP20070094T3 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0310962A GB0310962D0 (en) 2003-05-13 2003-05-13 Novel compounds
GB0407391A GB0407391D0 (en) 2004-03-31 2004-03-31 Novel compounds
PCT/EP2004/005083 WO2004101587A1 (en) 2003-05-13 2004-05-11 Novel 14 and 15 memberred-ring compounds

Publications (1)

Publication Number Publication Date
HRP20070094T3 true HRP20070094T3 (hr) 2008-05-31

Family

ID=33454579

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20070094T HRP20070094T3 (hr) 2003-05-13 2004-05-11 NOVI 14- i 15-EROČLANI PRSTENASTI SPOJEVI

Country Status (15)

Country Link
US (1) US20070293472A1 (https=)
EP (1) EP1628989B1 (https=)
JP (1) JP2006528667A (https=)
AR (1) AR044304A1 (https=)
AT (1) ATE348837T1 (https=)
CA (1) CA2525455A1 (https=)
CL (1) CL2004001012A1 (https=)
DE (1) DE602004003809T2 (https=)
DK (1) DK1628989T3 (https=)
ES (1) ES2278319T3 (https=)
HR (1) HRP20070094T3 (https=)
PL (1) PL1628989T3 (https=)
PT (1) PT1628989E (https=)
SI (1) SI1628989T1 (https=)
WO (1) WO2004101587A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552682T3 (es) 2003-03-10 2015-12-01 Merck Sharp & Dohme Corp. Agentes antibacterianos novedosos
BRPI0510328A (pt) * 2004-05-06 2007-10-23 Glaxosmithkline Zagreb macrolìdeos ligados a éster úteis para o tratamento de infecções microbianas
GB0424961D0 (en) * 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
WO2007054295A1 (en) * 2005-11-09 2007-05-18 Glaxo Group Limited New 4*-substituted erythromycin derivative
GB0424958D0 (en) * 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
JP2008540503A (ja) 2005-05-10 2008-11-20 グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ 細菌感染症の処置に有用なエーテル結合マクロライド
EP1945652A1 (en) * 2005-11-09 2008-07-23 Glaxo Group Limited Macrolones
CN105732745A (zh) 2007-10-25 2016-07-06 森普拉制药公司 大环内酯类抗菌剂的制备方法
AU2009308182B2 (en) 2008-10-24 2016-05-19 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
CN105198944B (zh) 2010-05-20 2018-06-01 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
EP2613630A4 (en) 2010-09-10 2014-01-15 Cempra Pharmaceuticals Inc HYDROGEN BOND FOR THE PREPARATION OF FLUOROCHETOLIDES FOR THE TREATMENT OF DISEASES
MX2014011537A (es) 2012-03-27 2015-02-10 Cempra Pharmaceuticals Inc Formulaciones parenterales para la administracion de antibioticos macrolidos.
HK1217665A1 (zh) 2013-03-14 2017-01-20 森普拉制药公司 用於治療呼吸道疾病的方法及其製劑
RU2015138797A (ru) 2013-03-15 2017-04-24 Семпра Фармасьютикалс, Инк. Конвергентные способы получения макролидных антибактериальных агентов

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4180654A (en) * 1978-01-03 1979-12-25 Pfizer Inc. 4"-Deoxy-4"-acylamido derivatives of oleandomycin, erythromycin and erythromycin carbonate
US4512982A (en) * 1984-04-13 1985-04-23 Pfizer Inc. 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method
US4686207A (en) * 1985-11-12 1987-08-11 Abbott Laboratories Erythromycin A 11,12-carbonates and method of use
WO1990011288A1 (en) * 1989-03-28 1990-10-04 Abbott Laboratories Erythromycin derivatives
AU3710695A (en) * 1995-04-27 1996-11-18 Laboratorios Aranda, S.A. De C.V. Quinolonylcarboxyerythromycin derivatives and pharmaceutical compositions containing them
JP2002502366A (ja) * 1996-05-07 2002-01-22 アボット・ラボラトリーズ ３―デスクラジノース―２，３―無水エリスロマイシン誘導体
EP0895999A1 (en) * 1997-08-06 1999-02-10 Pfizer Products Inc. C-4" substituted macrolide antibiotics
GB0025688D0 (en) * 2000-10-19 2000-12-06 Glaxo Group Ltd Macrolides
JP4311203B2 (ja) * 2001-08-08 2009-08-12 大正製薬株式会社 １１ａ−アザライド化合物及びその製造方法
GB0127349D0 (en) * 2001-11-14 2002-01-02 Glaxo Group Ltd Macrolides
GB0225384D0 (en) * 2002-10-31 2002-12-11 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
EP1628989B1 (en) 2006-12-20
AR044304A1 (es) 2005-09-07
CA2525455A1 (en) 2004-11-25
ATE348837T1 (de) 2007-01-15
EP1628989A1 (en) 2006-03-01
DE602004003809D1 (de) 2007-02-01
DK1628989T3 (da) 2007-10-08
CL2004001012A1 (es) 2005-03-18
PL1628989T3 (pl) 2007-05-31
JP2006528667A (ja) 2006-12-21
PT1628989E (pt) 2007-03-30
US20070293472A1 (en) 2007-12-20
DE602004003809T2 (de) 2007-10-11
SI1628989T1 (sl) 2007-06-30
WO2004101587A1 (en) 2004-11-25
ES2278319T3 (es) 2007-08-01

Similar Documents

Publication Publication Date Title
HRP20070094T3 (hr) NOVI 14- i 15-EROČLANI PRSTENASTI SPOJEVI
YU48088B (sh) Derivati indola
KR950704313A (ko) 5-아릴인돌 유도체 및 세로토닌(5-ht₁)작용물질로서의 그의 용도(5-arylindole derivatives and their use as serotonin(5-ht₁)agonists)
AR082994A1 (es) Derivados de pirazina como bloqueadores del canal epitelial de sodio
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
BR9103433A (pt) Derivados de 4-benzil-isoxazol
HRP20080236T3 (en) Quinoline derivatives as phosphodiesterase inhibitors
AR007077A1 (es) Derivados tetrahidroisoquinolina, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, el uso de los mismos parala fabricacion de un medicamento
IE901799L (en) Anti inflammatory aminophenol derivatives
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
PE20001289A1 (es) Nuevos antibioticos macrolidos
AR035254A1 (es) Derivados fluorquinolonicos de oxazolidinonas utiles como antibacterianos, procedimiento para su obtencion y su utilizacion para la preparacion de una composicion farmaceutica
YU6799A (sh) Derivati tetrahidrohinolina kao antagonisti eaa
CO5690593A2 (es) Nuevos derivados de pirimidin 2-amina
AR053311A1 (es) Macrolonas - quinolonas amino sustituidas
PE69398A1 (es) Antagonistas de receptor de benzoxazinona dopamina d4
AR049269A1 (es) Macrolidos unidos por esteres, utiles para el tratamiento de infecciones microbianas. procesos de preparacion y composiciones farmaceuticas.
PE25998A1 (es) DERIVADOS DE OCTAHIDRO-PIRROLO(1,2-a)-PIRAZINA 2,7-SUSTITUIDOS
DK304289A (da) Benzenderivater
DE68909855D1 (de) 2-[(4-Piperidinyl)methyl]-1,2,3,4-tetrahydroisochinolin-Derivate, ihre Herstellung und ihre therapeutische Verwendung.
DE69910568D1 (de) Furopyridinderivate und ihre therapeutische verwendung
AR064480A1 (es) Derivados de espiro-piperidina
AR044308A1 (es) Compuesto de macrolido de 14 y 15 miembros sustituido en la posicion 4", procedimiento para la preparacion del mismo, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
AR044305A1 (es) Compuesto de macrolido de 14 y 15 miembros sustituido en la posicion 4'', procedimiento para la preparacion del mismo, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende